Journal of Assisted Reproduction and Genetics

, Volume 19, Issue 4, pp 164–168

Ascorbic Acid Supplement During Luteal Phase in IVF


  • Georg Griesinger
    • Department of Obstetrics and GynecologyUniversity of Vienna
    • Institut fuer Sterilitaetsbetreuung
  • Katharina Franke
    • Institut fuer Sterilitaetsbetreuung
  • Cordelia Kinast
    • Institut fuer Sterilitaetsbetreuung
  • Alexandra Kutzelnigg
    • Institut fuer Sterilitaetsbetreuung
  • Sandra Riedinger
    • Institut fuer Sterilitaetsbetreuung
  • Sandor Kulin
    • Kaali Intezet
  • Steven G. Kaali
    • Kaali Intezet
    • Institut fuer Sterilitaetsbetreuung

DOI: 10.1023/A:1014837811353

Cite this article as:
Griesinger, G., Franke, K., Kinast, C. et al. J Assist Reprod Genet (2002) 19: 164. doi:10.1023/A:1014837811353


Purpose: To evaluate the impact of ascorbic acid of different doses as additional support during luteal phase in infertility treatment by means of a prospective, randomized, placebo-controlled, group comparative, double-blind study. Methods: Voluntary daily oral intake of either ascorbic acid (1, 5, or 10 g/day) or Placebo for 14 days after follicle aspiration for IVF-ET procedure. Data was obtained on 620 cases of women, age <40 years, undergoing first IVF-embryo transfer cycles in two private out-patient infertility clinics. All women were stimulated by the same protocol. The mean age was 31.73 (±4.4 SD) years. Results: No differences in clinical pregnancy rate and implantation rate were noted in statistical logistic regression analysis between the four intake groups. Conclusions: There was no clinical evidence of any beneficial effect, as defined by main outcome measures, of ascorbic acid on IVF-ET. Our data suggest there is no obvious value of high dosed intake of vitamin C during luteal phase in infertility treatment.

ascorbic acidfertilityIVFluteal phase

Copyright information

© Plenum Publishing Corporation 2002